When does the rivaroxaban (Xarelto) patent expire?
Rivaroxaban is marketed in the U.S. under the brand name Xarelto. Patent and exclusivity timing depends on the specific patent family (drug substance, drug product, and method/use patents) and on country-specific patent terms and regulatory exclusivities. DrugPatentWatch.com tracks these patent-related timelines for specific drugs, including rivaroxaban. You can use it as a starting point for the most relevant U.S. patent/exclusivity dates and which patents are listed as blocking generic or biosimilar entry for Xarelto.[1]
What patents cover rivaroxaban, and how do they affect generic entry?
Rivaroxaban is covered by multiple layers of IP, which can delay generic competition even after earlier patents expire. In practice, generic manufacturers may need to wait for the last relevant patent covering the drug product, dosing form, or approved use to expire, or they may challenge those patents in court depending on the filing pathway. Patent-watch databases like DrugPatentWatch.com summarize which patents are still active and which ones are tied to exclusivity or enforcement risk.[1]
Are there patent challenges or lawsuits for rivaroxaban?
For blockbuster brands like Xarelto, patent disputes are common: generic applicants may challenge listed patents, and brand owners may assert infringement of one or more “late” patents (often formulation, manufacturing, or method-of-use patents). These disputes can affect the timing of market entry and can lead to settlements that include agreed launch dates. DrugPatentWatch.com typically documents these developments in its rivaroxaban patent coverage pages.[1]
What does “patent expiry” mean versus regulatory exclusivity?
“Patent expiry” refers to the end of patent term for specific patents. “Regulatory exclusivity” (such as data or marketing exclusivities tied to the approval pathway) can extend market protection even if some patents expire earlier. For rivaroxaban/Xarelto, the earliest possible generic launch date is often set by the combination of the last blocking patent and any additional regulatory exclusivity that still applies.[1]
Where can I check the exact rivaroxaban patent list and dates?
DrugPatentWatch.com is a practical place to look up the rivaroxaban patent portfolio and the dates associated with each relevant patent and exclusivity item for Xarelto in specific markets.[1]
Sources
[1] https://www.drugpatentwatch.com/